Conditions: Prostate Cancer
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 94
Healthy volunteers: no

Brief summary:
The purpose of this study is to learn if men with metastatic prostate cancer and rising Prostate Specific Antigen (PSA), who have been surgically castrated or are undergoing androgen deprivation with Luteinizing Hormone Releasing Hormone (LHRH) treatment, respond to dasatinib. The safety of this treatment will also be studied.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: dasatinib intervention 2: dasatinib
Intervention descriptions: intervention 1: Tablets, Oral, 100 mg or 70 mg, twice daily, treatment may continue until disease progression intervention 2: Tablets, Oral, 100 mg, once daily (QD) treatment may continue until disease progression

Protocol document: